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Viruses are a form of life that possess genes but do not have a cellular structure. Viruses do not have their own metabolism, and they 
require a host cell to make new products; therefore, they cannot naturally reproduce outside a host cell. The objective of this paper is to 
present the basic practical clinical roles of viruses in patients with hematological diseases including malignancies and non-malignan-
cies, as well as those undergoing hematopoietic cell transplantation (HCT), with the focus on herpesviruses causing latent infections in 
severely immunocompromised patients. From the hematologist point of view, viruses can play a major role in four conditions: causing 
infections; causing lymphoproliferations and/or malignancies; causing (pan)cytopenia; and used as vectors in treatment (e.g., gene ther-
apy, CAR-T cells). Taking into account the role of viruses in hematology, infection is the most frequent condition. Among DNA viruses, the 
highest morbidity potential for human is expressed by Herpesviridiae (herpesviruses), Adenoviridae (adenovirus; ADV), Polyomavirus 
(BKV, JCV), and Bocavirus. RNA viruses can play a role in pathogenesis of different clinical conditions and diseases: lymphoproliferative 
disorders and malignancy, possibly causing NHL, AML, MDS, and others (HCV, HIV, and others); pancytopenia and aplastic anemia (HIV, 
HCV, Dengue virus); respiratory infections (community-acquired respiratory virus infections; CARV) caused by Orthomyxoviruses (e.g. 
influenza A/B), Paramyxoviruses (e.g. human parainfluenza virus PIV-1, -2, -3, and -4; respiratory syncytial virus RSV-A and -B), picornavi-
ruses (e.g., human rhinovirus), coronaviruses (e.g., human coronavirus), Pneumoviridiae (e.g., human metapneumovirus), and potentially 
other viruses.
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Introduction
Viruses are a form of life that possess genes but do not have a cellular 
structure. Viruses do not have their own metabolism, and they require 
a host cell to make new products; therefore, they cannot naturally 
reproduce outside a host cell [1]. The complete set of viruses in an 
organism or habitat is called the virome; for example, all human viruses 
constitute the human virome [2]. Although there are millions of different 
types of viruses, only about 5,000 types have been described in detail 
[3]. A virus has either a DNA or an RNA genome and is called a DNA 
virus or an RNA virus, respectively.
The objective of this paper is to present the basic practical clinical roles of 
viruses in patients with hematological diseases including malignancies 
and non-malignancies, as well as those undergoing hematopoietic cell 
transplantation (HCT), with the focus on herpesviruses causing latent 
infections in severely immunocompromised patients.
Classification
The current classification of viruses was developed by The International 
Committee on Taxonomy of Viruses (ICTV). As of June 2019, 14 
orders, 143 families, 64 subfamilies, 846 genera and almost 5000 
species of viruses have been defined by the ICTV. The orders are 
the Caudovirales, Herpesvirales, Ligamenvirales, Mononegavirales, 
Nidovirales, Ortervirales, Picornavirales, Bunyavirales, Tymovirales, 
Muvirales, Serpentovirales, Jingchuvirales, Goujianvirales, and 
Articulavirales (Virus Metadata Resource; https://talk.ictvonline.org/
taxonomy/vmr/).
Baltimore classification of viruses is based on the DNA or RNA of virus 
and method of mRNA synthesis [4]. Viral genomes may be RNA or 
DNA, single-stranded (ss) or double-stranded (ds), and may or may 
not use reverse transcriptase (RT). Additionally, ssRNA viruses may be 
either sense (+) or antisense (−). The vast majority of viruses have RNA 
genomes. Baltimore classification divides viruses into seven groups 
(Tab. I).
Role of viruses in hematology
From the hematologist point of view, viruses can play a major role in 
four conditions: causing infections; causing lymphoproliferations and/
or malignancies; causing (pan)cytopenia; and used as vectors in 
treatment (e.g., gene therapy, CAR-T cells) (Tab. II).
Taking into the role of viruses in hematology, infection is the most 
frequent condition. Among DNA viruses, the highest morbidity potential 
for human is expressed by Herpesviridiae (herpes viruses), Adenoviridae 
(adenovirus; ADV), Polyomavirus (BKV, JCV), and Bocavirus.
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RNA viruses can play a role in pathogenesis of different clinical 
conditions and diseases: lymphoproliferative disorders and 
malignancy, possibly causing NHL, AML, MDS, and others (HCV, 
HIV, and potentially Dengue virus, Zika virus, Chickungunya 
virus); pancytopenia and aplastic anemia (HIV, HCV, Dengue 
virus); respiratory infections (community-acquired respiratory virus 
infections; CARV) caused by Orthomyxoviruses (e.g., influenza 
A/B), Paramyxoviruses (e.g., human parainfluenza virus PIV-1, -2, 
-3, and -4; respiratory syncytial virus RSV-A and -B), Picornaviruses 
(e.g., human rhinovirus), coronaviruses (e.g., human coronavirus), 
Pneumoviridiae (e.g., human metapneumovirus), and potentially 
other viruses.
Diagnostics of viral infections in hematological 
patients
Laboratory test for viral infections with focus on latent and chronic 
infections should be performed in many hematological conditions, 
especially at diagnosis of the disease, and before HCT (both in 
recipient and donor). Additionally, after HCT monitoring for CMV and 
EBV, reactivation is mandatory in allo-HCT setting, and for several 
other viruses depending on clinical signs and symptoms (Tab. III).
Viral infections
Viral infections are a major issue for hematopoietic cell transplant 
(HCT) recipients. The most important viral pathogens in this group 
of patients include herpes simplex viruses (HSV-1 and HSV-2), 
varicella zoster virus (VZV), cytomegalovirus (CMV), Epstein-Barr 
Virus (EBV), human herpes 6 virus (HHV6), adenovirus (ADV), BK 
virus (BKV), influenza, parainfluenza, respiratory syncytial virus 
(RSV), rhinovirus, and norovirus. Other pathogenic viruses include 
enteroviruses, HIV, hepatitis, JCV, and parvovirus (PVB19).
Reactivation of latent infections with herpes viruses may lead to 
various disease manifestations, regardless of its primary acquisition 
after the transplant. Unlike in the general immunocompetent 
population, with typical clinical manifestations of infection ranging 
from asymptomatic to mild or moderate symptoms, HCT recipients 
may frequently develop much more severe disease.
It is essential to identify patients at risk for reactivation of latent viruses, 
as active infection and diseases can often be prevented with prophylaxis 
and preemptive monitoring during the most critical time periods.
Herpes viruses
Herpesviridae create a large family of double-stranded DNA viruses 
with specific and unique biologic features, enabling them to establish 
latency program after primary infection in human prior to reactivation 
later in life. With respect to taxonomy, there are three subfamilies: 
alpha-, beta-, and gamma-herpes-viridiae, which include nine known 
human herpesviruses (Tab. IV).
In the most severely immunocompromised patients, which comprise 
mainly recipients of allo-HCT from unrelated or mismatched donor, 
four herpesviruses play a major role in chronic latent and relapsing 
infections including CMV, EBV, HHV6B, and VZV. So far, no 
pathogenicity was shown for HHV-6A virus. These four viruses are 
described and discussed in this article. Basic characteristics of these 
four herpesviruses are shown in table V [5–8].
Herpes simplex virus. HSV-1 and HSV-2 infection is usually 
associated with mucocutaneous disease in the orofacial region 
(85%–90%), and rarely in the esophageal and genital area. Rare 
Table I. Baltimore classification of viruses
Group Category Examples
I dsDNA viruses Adenoviruses, 
Herpesviruses, Poxviruses
II ssDNA viruses (+ strand or „sense”) 
DNA
Parvoviruses
III dsRNA viruses Reoviruses
IV (+)ssRNA viruses (+ strand or sense) 
RNA
Picornaviruses, Togaviruses




VI ssRNA-RT viruses (+ strand or sense) 
RNA with DNA intermediate in 
life-cycle
Retroviruses
VII dsDNA-RT viruses DNA with RNA 
intermediate in life-cycle
Hepadnaviruses
Table II. Role of viruses in hematology
Role Examples
Causing infections Episodic infections (CARV)
Latent infections (herpesviruses, ADV, BKV, JCV)




EBV, HTLV (HIV, HCV)
Causing 
pancytopenias 
PVB19, HAV, HCV, HIV, DENV
Used in treatment Retroviruses, Lentiviruses (vectors for CAR-T cells, 
gene therapy)
Abbreviations in text.
Table III. Mandatory screening tests for viral infections in 
hematology
Clinical situation Viral test
Malignancy at diagnosis CMV, EBV, HIV, HBV, HCV (serology)
Before HCT CMV, EBV, HIV, HBV, HCV, (HSV, VZV) (serology)
Donor HSC CMV, EBV, HIV, HBV, HCV (serology)
After allo-HCT CMV, EBV (NAT)
Thrombocytopenia CMV, EBV, HIV
Pancytopenia CMV, EBV, HIV, HAV, HBV, HCV, PVB19
Leukocytosis EBV, CMV, HCV
Respiratory infection CARV, ADV, CMV
Hemorrhagic cystitis BKV, ADV, CMV
Encephalitis HHV6, CMV, EBV, JCV, VZV, HSV
Hepatitis HAV, HBV, HCV, HDV, HEV and other
NAT (nucleic acid test); other abbreviations in text.
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manifestations are meningitis, encephalitis, pneumonia, and 
hepatitis. Mucocutaneous HSV disease is diagnosed clinically 
and can be confirmed by PCR. HSV meningitis and encephalitis 
should be confirmed by PCR in cerebrospinal fluid. Antiviral drug 
prophylaxis is not recommended in HSV-seronegative patients 
after HCT (except anti-VZV prophylaxis). HSV-seropositive patients 
should receive antiviral drug prophylaxis after allo-HCT. Intravenous 
acyclovir 250 mg/m2 or 5 mg/kg every 12 h, oral acyclovir 3 x 200 
to 2 x 800 mg/day, oral valaciclovir 2 x 500 mg/day, or famciclovir 
2 x 500 mg/day can be used, for a period of at least 4 weeks after 
HCT in VZV-seronegative patients. Intravenous acyclovir remains 
the therapy of choice for severe mucocutaneous or visceral HSV 
disease. Intravenous acyclovir 250 mg/m2 or 5 mg/kg every 8 h for 
7–10 days is the therapy of choice for severe mucocutaneous or 
visceral HSV disease. Oral acyclovir, from 5 x 200 to 5 x 400 mg/day, 
valaciclovir 2 x 500 mg/day, or famciclovir 2 x 500 mg/day for 10 days 
are considered as alternatives for less serious manifestations of HSV 
disease. For HSV pneumonia or HSV meningitis and encephalitis, i.v. 
acyclovir 500 mg/m2 or 10 mg/kg every 8 h for at least 14–21 days is 
recommended. HSV resistance occurs in approximately 5%–15% of 
patients and foscarnet or cidofovir is second-line therapy [5].
HHV-7 primary infection in young children (<5y) causes exanthema 
subitum (roseola) and rarely status epilepticus with fever. Reactivation 
of HHV-7 occurs in about 10% of patients after allo-HCT. Clinically, 
overt HHV-7 detection after HCT is rare and might be associated with 
CNS disease (encephalitis or myelitis). Diagnosis of HHV-7 is made 
by qPCR. Usually, infection with HHV-7 does not require specific 
treatment [6].
HHV-8 (KSHV, Kaposi’s sarcoma-associated herpesvirus) is 
the cause of Kaposi’s sarcoma (KS), as well as primary effusion 
lymphoma and Castleman’s disease. KS is extremely rare after HCT 
with skin involvement, fever, and marrow aplasia with plasmocytosis. 
Pediatric cases might have visceral involvement. Diagnosis of 
HHV-8 is made by qPCR. KS can be confirmed histopathologically 
as malignant tumor. In skin manifestation, surgical excision 
or electrochemotherapy is the preferable approach. For other 
manifestations, possible options include the following: interferon-
alpha, chemotherapy, and radiotherapy [9,10]. The use of antiviral 
treatment is not recommended.
Herpes viruses seroprevalence: increasing 
with age
The human herpesviruses, such as CMV, EBV, HHV6, and VZV, 
are being the agents of a global infection although differences in the 
















Table V. Basic characteristics of CMV, EBV, HHV6, and VZV infections in HCT setting
Characteristics CMV EBV HHV6 VZV
Taxonomy HHV-5 HHV-4 HHV-6 HHV-3
Family Herpesviridae Herpesviridae Herpesviridae Herpesviridae
Subfamily beta gamma beta alpha
Nucleic acid ds DNA ds DNA ds DNA ds DNA 
Year first identified 1956 1964 1986 1888
Incubation period 3-12 weeks 3-7 weeks 1-2 weeks 2-3 weeks
Seroprevalence in children 30-50% 30-50% First infection in first two 
years of life; (CIHHV6: 1%)
67% (age: 1-4y)





Yes (rare; asymptomatic) Congenital (vertical)  




Confirmed modes of trans-
mission
With blood and other 
body fluids (saliva) 
With saliva and other 
body fluids;
Kissing disease (saliva) 
With saliva and other body 
fluids























*EXPOSURE: face-to-face contact of 5 min or more with a person with varicella or with an immunocompromised patient with disseminated HZ, or intimate contact (touching or hugging) 
with a person with HZ (acc. to ECIL-2)
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seroprevalence exist between countries: it is the well-documented 
fact in case of CMV [5–8]. CMV acquisition in a general population 
is characterized by an age-dependent rise in seropositivity, which 
correlates most closely with socioeconomic level as well as race, 
similarly to other herpesviruses [11]. Seroprevalence of CMV varies 
from about 40%–50% in highly developed countries to over 90% of 
population in the developing countries, with the rate from about 30% 
in childhood to over 50% of women of childbearing age and even up 
to 60%–70% in adults. However, the incidence slightly decreases with 
the calendar year. Nevertheless, in population of highly developed 
countries, CMV acquisition still occurs at a rate of 1%–7% per year 
[8, 9,11–13].
There is an exception in case of HHV-6, as apart from seroprevalence 
after acquired infection, mainly in early childhood, there is a congenital 
phenomenon of chromosomally integrated HHV-6 (CIHHV-6), 
resulting from vertical transmission: inherited from mother or father. 
It occurs both in HHV-6A or HHV-6B with prevalence about 1% in the 
general population. In case of CIHHV-6, the virus HHV-6 present in 
every nucleated cell, and HHV-6 DNA can be easily detected in hair 
follicles and nails. In most cases, there is one copy of HHV-6 DNA/
leukocyte [14,15].
Clinical symptoms: many manifestations
Some of herpesviruses have a potential to play a role in pathogenesis 
of different diseases with various manifestations. This is well 
observed in case of EBV and CMV, and it happens also for HHV6 
and VZV (Tab. VI).
Also CIHHV-6 can be associated with several diseases. There is a 
good evidence of association with aGVHD and CMV reactivation [14]. 
It is probably associated with angina pectoris in general population, 
and there are known cases of hemophagocytosis with thrombotic 
microangiopathy in SCID patients, as well as encephalitis post-HCT.
Risk factors and incidence of reactivation
Risk factors of herpes virus recurrence after allo-HCT depend on 
the following: recipient (virus serology; age), donor (virus serology 
match; age; sex match; HLA match; type of family/unrelated 
donor; stem cell source), transplant (type of conditioning: TBI-or 
chemotherapy-based; T-cell depletion; intensity of myeloablative or 
reduced intensity conditioning, RIC), immunosuppressive treatment 
(prophylaxis, occurrence and treatment of acute and/or chronic 
GVHD; immunosuppressive drugs used in prophylaxis and/or 
therapy), as well as immune recovery after HCT (speed of immune 
reconstitution for B cells, T cells, NK cells; recovery of virus-specific 
cytotoxic T lymphocytes, CTLs) [8]. Incidence of reactivation in 
patients after HCT is presented in table VII.
The highest risk of CMV recurrence and CMV disease is reported 
for HCT CMV-seropositive recipients (R), regardless on donor (D) 
serostatus. The odds ratio for CMV recurrence is higher for R+ vs 
R- CMV-serostatus transplants (odds ratio: OR=8.0), D-/R+ vs D+/
R+ CMV-serostatus transplants (OR=1.2), unrelated/mismatched vs 
matched-family donor transplants (OR=1.6), and acute graft-versus-
host-disease vs others (OR=3.2) [8].
The highest risk for EBV reactivation and development of EBV-PTLD 
is in the case of donor seropositivity, as in majority of cases EBV-
PTLD after HCT is of donor origin [7].
In several studies, the relative frequency of herpes viruses 
reactivations was analyzed in population of patients after allo-HCT, 
sometimes also with frequency of other latent viruses. Schmidt-Hieber 
et al. [17] showed in CNS (patients with encephalitis) incidence of 
1.2% (32/2628), including: HHV6, 19%; EBV, 19%; HSV, 13%; JCV, 
9%; VZV, 6%; ADV, 3%; more than one virus, 16% (CMV+HHV6+JCV; 
HHV6+HHV7; CMV+HHV6; HSV+EBV; CMV+VZV+HSV+EBV). The 
1-year survival of patients after viral encephalitis was below 40%.
Table VI. Clinical syndromes and symptoms 
Clinical symptoms CMV EBV HHV6 A/B VZV




















*PTLD: Heterogeneous group of EBV diseases with neoplastic lymphoproliferation, developing after transplantation and caused by iatrogenic suppression of T-cell function
Table VII. Incidence of reactivation in patients after HCT
Incidence CMV EBV HHV6 VZV
Reactivation (without prophylaxis) 30%–35% Median 29%
(0.1%–63%)
30%–70% 25%–50%
Symptomatic clinical disease after 
HCT
1%–2%
up to 11% at 1y [8]
3%





MFD (matched family donor); MMUD (mismatched unrelated donor); CBT (cord blood transplantation); BM (bone marrow); PB (peripheral blood)
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Wu et al. [18] also analyzed the incidence of viral CNS reactivation 
of herpesviruses, with overall incidence of 12.4%. The most frequent 
were as follows: EBV, 57.1%; HSV1, 19.0%; CMV, 14.3%; VZV, 
4.8%, and mixed 4.8% (EBV+CMV).
Polish analyses [19–21] showed the incidence of viral reactivation in 
children: CMV, 29.2%; EBV, 24.3%; BKV, 22.8%; ADV, 5.2%, and the 
incidence of HHV6 was 1.5%; however, this virus was not usually being 
tested in all centers. The respective incidence in adults’ patients included 
the following: CMV, 24.7%; BKV, 5.9%; ADV, 2.9%; EBV, 1.9% [21].
Diagnostics before HCT: serology
Because of incidence and several strategies of prophylaxis and 
preemptive therapy, it is an universal agreement expressed in a 
number of guidelines, that in allo-HCT setting, both recipient and 
donor should be tested serologically (i.e., IgG antibodies) for CMV 
and EBV, while not for HHV6 and VZV markers. In auto-HCT 
setting, only CMV serology is usually required, but not EBV, HHV6, 
or VZV markers. Principles of diagnostics of reactivation and end-
organ disease are shown in table VIII. The definitive diagnosis of 
reactivation is confirmed by the presence of viral DNA detected by 
PCR. In case of HHV6, one must exclude CIHHV6, while in case of 
VZV diagnosis is usually clinical.
The proven diagnosis of herpes virus end-organ disease must be 
done from biopsy in case of CMV and EBV, from the presence of 
CSF DNA in case of HHV6, and clinical diagnosis with blood DNA 
for VZV.
Prophylaxis
With the variety of viruses, there is a variety of evidences on viral 
prophylaxis (Tab. IX). Only in case of CMV, there is a good quality 
of evidence to use antivirals. Nevertheless, so far it was not a 
recommended strategy because of its toxicity of antiviral drugs. 
Introduction of letermovir might possibly change this practice, what is 
happening already in many centers in other countries [22].
Passive immunization (specific immunoglobulins) is available for 
CMV (CMV-Ig) and VZV (VZ-Ig), whereas it is not available for EBV 
and HHV6. VZ-Ig is recommended for prophylaxis after exposure 
(up to 2 years after HCT) in IgG-negative transplant recipients [5]. 
CMV-Ig is recommended as an option only for treatment of CMV 
pneumonia, whereas it is not recommended for prophylaxis or 
preemptive treatment [22].
Preemptive approach
Preemptive approach is currently recommended as a post-
transplant strategy for CMV and EBV reactivation, whereas it is not 
recommended for HHV6 and not necessary for VZV infection. This 
approach is a result of frequency of reactivations and therapeutic 
Table VIII. Diagnostics of reactivation and disease after HCT
Diagnostics CMV EBV HHV6 VZV














Diagnosis of reactivation PCR PCR PCR Clinical + PCR
Most frequent disease 
manifestations
Pneumonia, GI tract PTLD Encephalitis Varicella/Zoster
Biopsy Required for proven 
diagnosis (except retinitis)
Required for proven 
diagnosis
Not required Not necessary
Definitive diagnosis Biopsy (CMV proteins) Biopsy (EBER, viral proteins) HHV6-DNA in CSF; exclusion of 
CIHHV6
Clinical symptoms +DNA-emia
Imaging Various PET Brain MRI often normal No
Additional methods DNA-emia (PCR) DNA-emia (PCR) DNA-emia (PCR) Clinical + PCR
p/s (plasma/serum); PET (positron emission tomography); CNS (central nervous system); other abbreviations in text.
Table IX. Possibilities of prophylaxis







Not known Avoiding contact
Specific
prophylaxis
Used as a strategy Weak recommendation Not recommended Mandatory in IgG+
(allo ≥12 months; auto 3-6 months)
Method Antivirals: GCV (ganciclovir), 
LMV (letermovir)
Anti-CD20 NO Acyclovir (valaciclovir)
Possible passive immunization 
after exposure
CMV-Ig Not available Not available VZ-Ig 
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possibilities: antivirals for CMV (ganciclovir GCV and foscarnet FSC 
in first/second line, and cidofovir CDV in third line of therapy) [22], and 
anti-CD20 for EBV (rituximab) [23]. Preemptive therapy (also known 
as preemptive prophylaxis) should be based on a routine screening 
for blood DNA-emia by qPCR and administration of drugs in case of 
positive viremia, usually defined locally by specific cutoff value. It is 
recommended to start preemptive approach within first 4 weeks after 
HCT and to continue it at least up to day +100 or longer in case of risk 
factors for reactivation or presence of graft-versus-host disease and 
immunosuppressive therapy.
Treatment
The first-line treatment of end-organ disease is based on 
administration of GCV (2 x 5 mg/kg) or FSC (2 x 90 mg/kg) for CMV 
disease, rituximab 375 mg/m2 weekly for EBV disease, GCV or FSC 
for HHV6 disease, and acyclovir (3 x 500 mg/m2 intravenously or 5 
x 800 mg; pediatric dose 4 x 20 mg/kg orally) (Tab. X) [5, 6, 22, 23].
Vaccination
VZV is the only herpes virus for which vaccine is available/approved: 
live attenuated (LAZV: Zostavax, and LAVV: Varivax), heat-inactivated 
(V212; Phase III) (auto-HCT) [24], and recombinant (Shingrix; 
approved 2017; RZV, Phase III, ZOE-HSCT Trial) (presented during 
EBMT Annual Meeting 2019). So far, live attenuated vaccines are 
contraindicated both after allo- and auto-HCT at least up to 24 months 
after HCT. Afterwards, one dose of LAVV can be considered in VZV-
seronegative adult patients (two doses in children) with no GvHD, 
without immunosuppressive treatment, no relapse of underlying 
disease, and no treatment of immunoglobulins during the previous 
months; the second dose can be considered in adult seronegative 
patients or had no history of VZV infection [25–29]. In transplant 
setting, inactivated vaccines should be preferred to LAVZ. Still, more 
data are needed on allo-HCT [25–29].
Outcome of infection
Herpes virus infection is always regarded as a serious complications. 
The most frequent end-organ diseases have relatively poor outcome, 
with about 50% survival for CMV pneumonia, 70% for EBV-PTLD, 
and 50% for HHV6 encephalitis [30–32]. Only in case of VZV, the 
outcome is close to 100%; this is because of effective prophylaxis 
with acyclovir for at least 12 months after HCT. Positive risk factor 
for good outcome of infection is reduction of immunosuppressive 
treatment, if possible. On the other hand, another pitfalls of treatment 
of herpes virus infection are adverse events of antiviral therapy.
Herpes virus infections might have also an impact on transplant 
outcomes. The results are ambiguous. The summary, based on large 
studies, is presented in table XI.
Conclusions
Because of high worldwide seroprevalence and latency, infections 
with herpesviruses are, and will be, frequent. Current strategies of 
management of CMV and EBV are based on mandatory monitoring 
of DNA-emia and administration of preemptive therapy if DNA-emia 
is positive; however, pharmacological prophylaxis is a renewed 
possibility in case of CMV (letermovir) and is an option for EBV 
infection (rituximab). In case of HHV-6, no routine screening is 
Table X. Treatment of end-organ disease
Treatment CMV EBV HHV6 VZV
Treatment (first line) GCV/FSC Anti-CD20
+reduction of IST
GCV/FSC ACV





Treatment (resistant cases) GCV+FSC
CDV
+chemotherapy FSC; CDV (weekly; +probenecid)
Cellular therapy: Cytotoxic T-lymphocytes CMV-CTL* EBV-CTL* (Tabelecleucel) HHV6-CTL* NO
Off-the-shelf CTLs Yes* Yes* Yes*
Multi-specific CTLs Yes (CMV, EBV, HHV6, ADV, BKV)*
* limited availability; GCV (ganciclovir); FSC (foscarnet); CDV (cidofovir); (V)ACV (val)acyclovir); IST (immunosuppressive therapy); other abbreviations in text.
Table XI. Impact of herpes virus infections on transplant outcomes 
Outcome CMV [22, 33, 34] EBV [7, 35, 36] HHV6 [14–16] VZV [5, 37]
OS (overall survival) Decreased OS No effect Decreased OS? Decreased OS
RI (relapse incidence) No effect Replication: ↓RI? No effect No effect
NRM (non-relapse mortality) Replication: ↑NRM Replication:  ↑NRM? Replication:  ↑NRM?
Acute GVHD No? No? YES ( ↑ in CIHHV6) No
Chronic GVHD ↑ in repeated CMV infections Increased
(if: donor IgG+)
No? No
A c t a  H a e m a t o l o g i c a  P o l o n i c a
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recommended; however, in case of encephalitis, encephalopathy, 
myelosuppression, respective diagnostics should be performed, 
including test for CIHHV6. Finally, with acyclovir prophylaxis, it seems 
that VZV is under control of transplantologists and hematologists, 
and there are also possibilities for vaccination against this infection.
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